Recently published findings suggest that patients with CML, particularly men, have a 30% higher risk of developing secondary cancers; however the cause of this increased risk is unclear.
A recent study sought to determine the effect of ivermectin against CML cells, whether ivermectin can sensitize cells to BCR-ABL TKIs, and its mechanism of action.
A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.
The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients.
Adding midostaurin — a multi-targeted kinase inhibitor — to chemotherapy prolongs overall survival (OS) among patients with newly diagnosed AML and an FLT3 mutation.
The data showed a higher rate of death, including fatal infections, in the vadastuximab talirine arm compared with the chemotherapy-only arm.
The FDA approved daratumumab in combination with pomalidomide and dexamethasone for the third-line treatment of patients with multiple myeloma.
Early response-based treatment intensification with allo-SCT improved OS among adult patients with early thymic precursor T cell ALL.
Brentuximab vedotin significantly prolonged PFS with higher response rates compared with methotrexate or bexarotene among patients with CTCL.